Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Nivolumab in Combination with Trametinib with or without Dabrafenib for the Treatment of Newly Diagnosed, Progressive or Recurrent Low Grade or High Grade Childhood Gliomas

Trial Status: active

This phase I trial tests the safety, side effects and effectiveness of nivolumab in combination with trametinib with and without dabrafenib in treating patients with low grade or high grade childhood glioma that is newly diagnosed, that is growing, spreading, or getting worse (progressive), or that has come back after a period of improvement (recurrent). Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the tumor, and may interfere with the ability of tumor cells to grow and spread. Both trametinib and dabrafenib are kinase inhibitors and block a molecular pathway known as mitogen-activated protein kinase (MAPK) pathway which may help keep tumor cells from growing. Dabrafenib also blocks certain proteins made by the mutated BRAF gene, which may help keep tumor cells from growing. Currently both trametinib and dabrafenib are approved treatments, but may not be enough to control or treat the brain tumor. Giving nivolumab in combination with trametinib and dabrafenib may be safe and tolerable and may be more effective than the combination of nivolumab and trametinib without dabrafenib in treating patients with newly diagnosed, progressive or recurrent low grade or high grade childhood glioma.